Inventor
KRAYNOV VADIM
US31 patents
⚠️ This page may combine multiple inventors who share the name “KRAYNOV VADIM”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
AMBRX INC
20 patentsUS8012931B2Sep 6, 2011
Modified FGF-21 polypeptides and their uses
AMBRX INC76 citations98
US8383365B2Feb 26, 2013
Methods of making FGF-21 mutants comprising non-naturally encoded phenylalanine derivatives
AMBRX INC48 citations96
US10253083B2Apr 9, 2019
Therapeutic uses of modified relaxin polypeptides
AMBRX INC11 citations92
US9975936B2May 22, 2018
Nucleic acids encoding modified FGF-21 polypeptides comprising non-naturally occurring amino acids
AMBRX INC12 citations92
US9567386B2Feb 14, 2017
Therapeutic uses of modified relaxin polypeptides
AMBRX INC14 citations92
US9079971B2Jul 14, 2015
Modified FGF-21 polypeptides comprising non-naturally occurring amino acids
AMBRX INC19 citations92
US9517273B2Dec 13, 2016
Methods of treatment using modified FGF-21 polypeptides comprising non-naturally occurring amino acids
AMBRX INC15 citations91
US9452222B2Sep 27, 2016
Nucleic acids encoding modified relaxin polypeptides
AMBRX INC14 citations90
US10751391B2Aug 25, 2020
Methods of treatment using modified relaxin polypeptides comprising a non-naturally encoded amino acid
AMBRX INC6 citations83
US10702588B2Jul 7, 2020
Modified relaxin polypeptides comprising a non-naturally encoded amino acid in the A chain
AMBRX INC7 citations83
US9962450B2May 8, 2018
Method of treating heart failure with modified relaxin polypeptides
AMBRX INC9 citations83
US10961291B2Mar 30, 2021
Modified FGF-21 polypeptides and their uses
AMBRX INC1 citations72
US10377805B2Aug 13, 2019
Modified FGF-21 polypeptides comprising non-naturally encoding amino acids and their uses
AMBRX INC2 citations72
US10954270B2Mar 23, 2021
Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives
AMBRX INC2 citations69
US11993637B2May 28, 2024
Modified FGF-21 polypeptides with non-naturally encoded amino acids
AMBRX INC0 citations62
US11786578B2Oct 17, 2023
Modified relaxin polypeptides and their uses
AMBRX INC0 citations62
US11439710B2Sep 13, 2022
Nucleic acids encoding modified relaxin polypeptides
AMBRX INC0 citations62
US11311605B2Apr 26, 2022
Methods of treating heart failure and fibrotic disorders using modified relaxin polypeptides
AMBRX INC0 citations62
US11542310B2Jan 3, 2023
Modified bovine G-CSF polypeptides and their uses
AMBRX INC0 citations61
US11420999B2Aug 23, 2022
Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives
AMBRX INC0 citations59
KRAYNOV VADIM
4 patentsUS8735539B2May 27, 2014
Relaxin polypeptides comprising non-naturally encoded amino acids
KRAYNOV VADIM36 citations96
US8329869B2Dec 11, 2012
Modified interferon beta polypeptides and their uses
KRAYNOV VADIM21 citations91
US8114630B2Feb 14, 2012
Modified interferon beta polypeptides and their uses
KRAYNOV VADIM18 citations91
US9938333B2Apr 10, 2018
Modified leptin polypeptides and their uses
KRAYNOV VADIM2 citations71
SCRIPPS RESEARCH INST
3 patentsUS7662644B2Feb 16, 2010
Labeled peptides, proteins and antibodies and processes and intermediates useful for their preparation
SCRIPPS RESEARCH INST2 citations59
US7176037B2Feb 13, 2007
Labeled peptides, proteins and antibodies and processes and intermediates useful for their preparation
SCRIPPS RESEARCH INST4 citations59
US7745377B2Jun 29, 2010
Labeled peptides, proteins and antibodies and processes and intermediates useful for their preparation
SCRIPPS RESEARCH INST0 citations48